Moderna, mRNA and bird flu

US health dept providing Moderna $590 mn to speed mRNA bird flu vaccine
US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new pandemic grow.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
U.S. Awards $590 Mln To Moderna For MRNA Pandemic Influenza Vaccine Development
The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Stomach bug,” “cruise-ship virus,” “winter vomiting disease”—all are nicknames for norovirus, the top cause of vomiting, ...
The Boston Globe5d
Moderna shares plunge after company cuts vaccine sales outlook
Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...